H3-DYNAMICS
15.12.2022 14:34:41 CET | Business Wire | Press release
H3 Dynamics and HyLight have joined forces to bring new long range, sustainable and quiet unmanned airships to a range of commercial applications. Traditionally, airships use combustion engines for their propulsion power. With new hydrogen propulsion system developments at H3 Dynamics, HyLight’s new breed of airships will now offer long-range zero emission flight and open a whole new category in air mobility. The two companies share a common goal, to decarbonize the aerial industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005555/en/
HyLight’s compact airship is powered by H3 Dynamics hydrogen air-mobility power systems
HyLight and H3 Dynamics started working together several months ago in France, and HyLight have now achieved a first successful hydrogen-electric flight test campaign in Milan, Italy. HyLight is an up and coming french start-up and one of the very few companies in the world that was able to demonstrate hydrogen as a viable power supply for small unmanned airships in real conditions. This was made possible with H3 Dynamics’ aerospace-grade hydrogen fuel cells - the smallest and lightest in the world - have pioneered hydrogen flight research from as early 2006.
HyLight’s unmanned airships move slowly but don’t need to consume any power to stay aloft. They can operate for days at a time with heavier payloads compared to conventional drones, to conduct long range inspection of critical energy assets like power-lines & pipelines or scan industrial infrastructure over long distances. Airships could also hover around specific areas to provide critical connectivity for large scale industrial sites - or provide vital communications after a natural disaster.
Based in Toulouse, H3 Dynamics is set on decarbonizing air mobility with clean hydrogen-electric propulsion, starting with enabling smaller unmanned systems - whether fixed wing, multi-rotor or VTOL platforms. Its ultra-light power technology is bringing new long electric flight durations to the global unmanned aviation market, which is set to reach $38 Billion by 2027.
Earlier this year H3 Dynamics flew the world’s first distributed hydrogen-electric nacelles on a small unmanned platform, proving the potential for larger size systems in bigger aircraft. H3 Dynamics has since become part of the “Toulouse Pioneers” group linked to the Aerospace History Museum “L’Envol des Pionniers”. The company plans to scale its solutions to larger unmanned and manned aviation platforms over the coming years.
HyLight will leverage H3 Dynamics’ international presence covering Europe, North and South America as well as Asia and Australia to bring “made in France” hydrogen-electric airships to the global market.
About HyLight: https://www.hylight.aero
HyLight wants to decarbonize the aerial data industry by providing long-range aerial data collection and analysis services using its unmanned airship systems for the inspection of power lines, pipelines, and railways. Its airship come with hydrogen electric propulsion making them sustainable, silent, efficient, and long-range to cover large areas or distances. The company was started in France and has recently demonstrated the first flight of its hydrogen-electric platform. HyLight was selected to participate in the 1st Batch of the acceleration program of Berkeley SkyDeck Europe, Milano ; the company is also a member of the Hub Drone Systematic and U-LTA and has been financially supported by La Région Grand Est in France.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is based in Toulouse, Austin and Singapore - and is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. The company’s initial commercial focus is on the scale up of autonomous digital services that link to networks of charging stations for off-the-shelf battery-drones, making way for BVLOS hydrogen UAS capability. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
